Autophagy and mitophagy in the context of doxorubicin-induced cardiotoxicity

Navid Koleini; Elissavet Kardami

doi:10.18632/oncotarget.16944

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Autophagy and mitophagy in the context of doxorubicin-induced cardiotoxicity

Navid Koleini and Elissavet Kardami _

PDF | HTML | How to cite

Oncotarget. 2017; 8:46663-46680. https://doi.org/10.18632/oncotarget.16944

Metrics: PDF 8802 views | HTML 10537 views | ?

Abstract

Navid Koleini1,2 and Elissavet Kardami1,2,3

1 Institute of Cardiovascular Sciences, St. Boniface Hospital Albrechtsen Research Centre, Winnipeg, Manitoba, Canada

2 Department of Physiology and Pathophysiology, Winnipeg, Manitoba, Canada

3 Department of Human Anatomy and Cell Sciences, University of Manitoba, Winnipeg, Manitoba, Canada

Correspondence to:

Elissavet Kardami, email:

Keywords: oncocardiology, anthracyclines, heart failure, impaired autophagy and mitophagy, lysosomal dysfunction

Received: November 25, 2016 Accepted: March 17, 2017 Published: April 07, 2017

Abstract

Doxorubicin (Dox) is a cytotoxic drug widely incorporated in various chemotherapy protocols. Severe side effects such as cardiotoxicity, however, limit Dox application. Mechanisms by which Dox promotes cardiac damage and cardiomyocyte cell death have been investigated extensively, but a definitive picture has yet to emerge. Autophagy, regarded generally as a protective mechanism that maintains cell viability by recycling unwanted and damaged cellular constituents, is nevertheless subject to dysregulation having detrimental effects for the cell. Autophagic cell death has been described, and has been proposed to contribute to Dox-cardiotoxicity. Additionally, mitophagy, autophagic removal of damaged mitochondria, is affected by Dox in a manner contributing to toxicity. Here we will review Dox-induced cardiotoxicity and cell death in the broad context of the autophagy and mitophagy processes.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 16944

Publication Alerts

Post-Publication Promotion

Publication Discount

Reviews:

Autophagy and mitophagy in the context of doxorubicin-induced cardiotoxicity

Abstract